1. In Vivo

Deals In Depth: May 2021

 
• By Maureen Riordan and Deanna Kamienski

Four $1b+ alliances were penned in May. Topping the list was Bristol-Myers Squibb’s deal with Agenus under which BMS will be granted a global exclusive license to the late-preclinical antibody program AGEN1777 along with a second undisclosed target. Agenus received a $200m up-front payment and could get up to $1.36bn in development, regulatory, and commercialization milestones, plus tiered royalties in the low double-digit to mid-teen range.

Deals In Depth
• Source: Alamy

In the top May M&A by deal value, private equity firm The Carlyle Group agreed to buy UK-based CDMO Vectura Group for $1.36bn. Vectura had initially been developing its own therapeutic pipeline of asthma and chronic obstructive pulmonary disease candidates until its VR475, a drug-device combination for severe uncontrolled asthma, was halted following a late-stage study failure at the end of 2018. The company rebranded itself as a CDMO in the field of inhalation technology in 2019. Financing reached $5.7bn in biopharma, $519m in device, and $1.6bn in diagnostics.

Exhibit 2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.